Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • Overview
  • Distribution
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • Request More Information
  • Journalists
  • Overview
  • Distribution by PR Newswire
  • Guaranteed Paid Placement
  • SocialBoost
  • Multichannel Amplification
  • All Products
  • Request More Information
  • Journalists
  • Request More Information
  • Journalists

Myocarditis Pipeline 2015 Report on Therapeutics Development


News provided by

Life Science Industry Research

22 Oct, 2015, 13:30 IST

Share this article

Share toX

Share this article

Share toX

PUNE, India, October 22, 2015 /PRNewswire/ --

New market research titled Myocarditis - Pipeline Review, H2 2015 is a report providing data and information that helps strengthen Myocarditis R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on Myocarditis pipeline spread across 33 pages, analyzing 2 companies, 7 drug profiles and supported with 14 tables and 11 figures is now available at http://www.lifescienceindustryresearch.com/myocarditis-pipeline-review-h2-2015.html .

This report provides comprehensive information on the therapeutic development for Myocarditis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocarditis and special features on late-stage and discontinued projects. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies mentioned in this Myocarditis pipeline H2 2015 review report include CEL-SCI Corporation and GlaxoSmithKline Plc. Drug profiles discussed in this report are CEL-1000, Cell Therapy to Activate IL-10 for Autoimmune Myocarditis and Inflammation, Cell Therapy to Target Flt3L for Autoimmune Myocarditis, chagas disease vaccine, Drugs to Inhibit Alpha Myosin for Cardiovascular Disorders, OBR-5340 and Small Molecule to Inhibit Coxsackievirus B3 3C Protease for Myocarditis. Order a copy of Myocarditis - Pipeline Review, H2 2015 market research report at http://www.lifescienceindustryresearch.com/purchase?rname=59648 .

The report provides a snapshot of the global therapeutic landscape of Myocarditis and reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. The report reviews key players involved in the therapeutics development for Myocarditis and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Myocarditis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Myocarditis pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products.

Another newly published market research titled Acute Heart Failure - Pipeline Review, H2 2015 is a report that provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies and helps identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. The research helps develop strategic initiatives by understanding the focus areas of leading companies, identify and understand important and diverse types of therapeutics under development for Acute Heart Failure as well as plan mergers and acquisitions effectively by identifying key players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Acute Heart Failure pipeline depth and focus of Indication therapeutics as well as develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope with the help of this Acute Heart Failure pipeline review report of 76 pages available at http://www.lifescienceindustryresearch.com/acute-heart-failure-pipeline-review-h2-2015.html .

Explore more reports on Pharmaceuticals market at http://www.lifescienceindustryresearch.com/category/pharmaceuticals .

About Us:   

LifeScienceIndustryResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


Media Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel:  +1-888-391-5441
[email protected]

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.